Last 206.60 INR
Change Today -6.15 / -2.89%
Volume 1.3M
SAPH On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

shasun pharmaceuticals ltd (SAPH) Snapshot

Open
213.30
Previous Close
212.75
Day High
218.90
Day Low
204.95
52 Week High
08/26/14 - 234.35
52 Week Low
09/4/13 - 59.75
Market Cap
12.4B
Average Volume 10 Days
2.2M
EPS TTM
5.34
Shares Outstanding
60.1M
EX-Date
07/30/14
P/E TM
38.7x
Dividend
1.00
Dividend Yield
0.48%
Current Stock Chart for SHASUN PHARMACEUTICALS LTD (SAPH)

Related News

No related news articles were found.

shasun pharmaceuticals ltd (SAPH) Related Businessweek News

No Related Businessweek News Found

shasun pharmaceuticals ltd (SAPH) Details

Shasun Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and enteric coating excipients. The company offers API products in the areas of pain management and musculoskeletal, central nervous system, cardiovascular, hyperphosphataemia, anti-infective, gastrointestinal, gastrointestinal, and other areas, as well as is developing API products in the areas of anti-depressant and anti-Parkinson’s. It is also engaged in the contract research and manufacturing services business, which provides chemistry and analytical services; and offers formulation development and manufacturing services for solid dosage products to pharmaceutical customers. In addition, the company is involved in biotechnology, nanotechnology, bulk substance, and generic drug development and manufacturing. It exports its products to North America, Europe, Asia, and Latin America. The company was formerly known as Shasun Chemicals and Drugs Ltd. Shasun Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Chennai, India.

Founded in 1976

shasun pharmaceuticals ltd (SAPH) Top Compensated Officers

Managing Director, Wholetime Director, Member...
Total Annual Compensation: 10.1M
Whole-Time Director and Member of Corporate S...
Total Annual Compensation: 6.5M
Wholetime Director and Member of Audit Commit...
Total Annual Compensation: 6.4M
Compensation as of Fiscal Year 2014.

shasun pharmaceuticals ltd (SAPH) Key Developments

Shasun Pharmaceuticals Limited Announces Changes in the Board of Directors

Shasun Pharmaceuticals Limited announced changes in the Board of Directors of the company with effect from August 06, 2014. Mr. M. Mohan, Whole time Director- EHS, has resigned from the Board. Dr. Arun Chandra Karmakar appointed as Director- Operations & EHS. The changes have been recorded and approved at the Board of Directors' Meeting held on August 06, 2014.

Shasun Pharmaceuticals Ltd, Board Meeting, Aug 06, 2014

Shasun Pharmaceuticals Ltd, Board Meeting, Aug 06, 2014.

Shasun Pharmaceuticals Ltd Announces Unaudited Consolidated and Standalone Earnings Results for the First Quarter Ended June 30, 2014

Shasun Pharmaceuticals Ltd. announced unaudited consolidated and standalone earnings results for the first quarter ended June 30, 2014. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 2,997.7 million compared to INR 2,167 million a year ago. Total income from operations was INR 3,137.2 million compared to INR 2,272.7 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 46.6 million compared to loss from operations before other income, finance costs and exceptional items of INR 183.7 million a year ago. Loss from ordinary activities before tax was INR 50.1 million compared to INR 168.3 million a year ago. Net loss for the period was INR 47.9 million compared to INR 65.7 million a year ago. Basic and diluted LPS before and after extraordinary items was INR 0.83 compared to INR 1.16 a year ago. EBITDA after R & D cost was INR 210 million compared to INR 72.3 million a year ago. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 2,369.8 million compared to INR 1,656.2 million a year ago. Total income from operations was INR 2,503.9 million compared to INR 1,759.5 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 113.7 million compared to loss from operations before other income, finance costs and exceptional items of INR 26.2 million a year ago. Profit from ordinary activities before tax was INR 36.6 million compared to loss from ordinary activities before tax of INR 77.6 million a year ago. Net profit for the period was INR 36.6 million compared to INR 25.1 million a year ago. Basic and diluted EPS before and after extraordinary items was INR 0.63 compared to INR 0.44 a year ago. EBITDA after R & D cost was INR 226.4 million compared to INR 77.1 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAPH:IN 206.60 INR -6.15

SAPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 817.55 INR -7.15
Dishman Pharmaceuticals & Chemicals Ltd 151.70 INR -4.90
Divi's Laboratories Ltd 1,565 INR +3.40
Jubilant Life Sciences Ltd 167.30 INR -3.05
Piramal Enterprises Ltd 689.15 INR +9.05
View Industry Companies
 

Industry Analysis

SAPH

Industry Average

Valuation SAPH Industry Range
Price/Earnings 36.4x
Price/Sales 0.9x
Price/Book 3.8x
Price/Cash Flow 13.6x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHASUN PHARMACEUTICALS LTD, please visit www.shasun.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.